Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
COPAXONE ® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE ® are redness, pain, swelling, ...
Momenta Pharmaceuticals, Inc. MNTA announced that its partner Sandoz (a Novartis NVS Company) has initiated the launch of once-daily Glatopa, the first generic version of Teva Pharmaceuticals’ TEVA ...
Teva’s injectable multiple sclerosis drug Copaxone has done a remarkably good job hanging on to market share in the face of oral competitors, generics and more. But Novartis aims to change that. On ...
BOSTON -- A copycat version of the multiple sclerosis (MS) drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a large head-to-head clinical trial, ...
Facing generic pricing pressure and Copaxone copycats, Teva Pharmaceutical has a lot riding on tardive dyskinesia (TD) drug Austedo and migraine med Ajovy. Hamstrung by the pandemic, Austedo came just ...
Teva’s efforts to protect the US patents on its multiple sclerosis blockbuster Copaxone ended in failure yesterday when an appeals court cleared the way for generic versions of the drug. Immediately, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results